What is ScreenIn3D?
ScreenIn3D is a UK-based biotechnology enterprise at the forefront of advanced lab-on-a-chip technologies. The company specializes in developing sophisticated microfluidic platforms designed to revolutionize cancer drug discovery. By simulating complex human tumor environments in vitro, ScreenIn3D provides pharmaceutical researchers with high-fidelity data that significantly improves the accuracy of drug efficacy testing. This approach not only reduces the reliance on traditional animal models but also accelerates the timeline for bringing life-saving oncology treatments to market. Positioned as a key player in the precision medicine ecosystem, the company integrates engineering excellence with biological insight to address the most pressing challenges in modern pharmacology.
How much funding has ScreenIn3D raised?
ScreenIn3D has raised a total of $1M across 1 funding round:
Seed
$1M
Seed (2025): $1M with participation from University of Strathclyde Glasgow, Nidobirds Ventures, The TRICAPITAL Syndicate, and Gabriel Investments
Key Investors in ScreenIn3D
University of Strathclyde Glasgow
A prominent academic institution based in Glasgow, focusing on research-led innovation and the commercialization of scientific breakthroughs.
Nidobirds Ventures
A venture firm specializing in rapid growth through equity participation and the provision of comprehensive operational infrastructure for early-stage startups.
The TRICAPITAL Syndicate
A Scottish-based business angel syndicate comprised of experienced entrepreneurs dedicated to funding and mentoring high-growth potential enterprises.
What's next for ScreenIn3D?
Looking ahead, the strategic deployment of the $1M will likely focus on expanding the company's laboratory infrastructure and enhancing its proprietary screening capabilities. As ScreenIn3D moves deeper into its growth phase, the focus will shift toward establishing high-value partnerships with global pharmaceutical entities and scaling its operational capacity to meet increasing demand for personalized cancer research tools. The company is expected to prioritize the validation of its platform across diverse tumor types, thereby solidifying its market position as an essential partner in the drug development pipeline. With a strong foundation of institutional support, ScreenIn3D is well-equipped to navigate the complexities of the biotech sector and drive long-term value for its stakeholders.
See full ScreenIn3D company page
